Corvus Pharmaceuticals Inc Market Cap ($815.97 Million)
Market Cap & Net Worth: Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals Inc market cap. Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has a market capitalization of $815.97 Million ($815.97 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9473 globally and #2650 in its home market, demonstrating a -7.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Corvus Pharmaceuticals Inc's stock price $9.70 by its total outstanding shares 84120944 (84.12 Million). Also see CRVS cash flow conversion for how efficiently the company converts equity into cash flow.
Corvus Pharmaceuticals Inc Market Cap History (2016–2026)
Corvus Pharmaceuticals Inc market cap history from 2016 to 2026. Data shows change from $1.20 Billion to $815.97 Million (-3.56% CAGR). Check Corvus Pharmaceuticals Inc (CRVS) share price today for real-time trading data and today's change.
Index Memberships
Corvus Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.03% | #273 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #1007 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.04% | #160 of 263 |
Weight: Corvus Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Corvus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Corvus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Corvus Pharmaceuticals Inc equity growth rate to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of CRVS by Market Capitalization
Companies near Corvus Pharmaceuticals Inc in the global market cap rankings as of November 4, 2026. Also see Corvus Pharmaceuticals Inc asset portfolio for a full breakdown of the balance sheet.
Key companies related to Corvus Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Corvus Pharmaceuticals Inc (2016–2026)
Market capitalization of Corvus Pharmaceuticals Inc from 2016 to today. Between 2016 and today, Corvus Pharmaceuticals Inc's market cap moved from $1.20 Billion to $ 815.97 Million, with a yearly change of -3.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $815.97 Million | +25.97% |
| 2025 | $647.73 Million | +43.93% |
| 2024 | $450.05 Million | +203.98% |
| 2023 | $148.05 Million | +107.06% |
| 2022 | $71.50 Million | -64.73% |
| 2021 | $202.73 Million | -32.30% |
| 2020 | $299.47 Million | -34.56% |
| 2019 | $457.62 Million | +48.23% |
| 2018 | $308.72 Million | -64.58% |
| 2017 | $871.49 Million | -27.55% |
| 2016 | $1.20 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Corvus Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $815.97 Million USD |
| MoneyControl | $815.97 Million USD |
| MarketWatch | $815.97 Million USD |
| marketcap.company | $815.97 Million USD |
| Reuters | $815.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-cen… Read more